XM does not provide services to residents of the United States of America.
P
P

Philips

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

FDA Says Philips Respironics Issues Mandatory Software Correction For Trilogy Evo, Ev300, EvoO2, Evo Universal

BRIEF-FDA Says Philips Respironics Issues Mandatory Software Correction For Trilogy Evo, Ev300, EvoO2, Evo Universal Oct 1 (Reuters) - FDA: FDA: PHILIPS RESPIRONICS ISSUES MANDATORY SOFTWARE CORRECTION UPDATES USE INSTRUCTIONS FOR TRILOGY EVO, EV300, EVOO2, AND EVO UNIVERSAL FDA: PHILIPS RESPIRONICS MANDATORY SOFTWARE CORRECTION FOR SOME VENTILATOR
P

Australia's 4DMedical jumps on distribution deal in US

BUZZ-Australia's 4DMedical jumps on distribution deal in US ** Shares of 4DMedical Ltd 4DX.AX jump 44.9% to A$0.645, set for their best day since Nov 13, 2023, if gains hold ** Medical technology firm says it has signed a distribution agreement with Dutch medical device maker Koninklijke Philips NV PHG.AS ** Co says, Philips will have exclusive distribution rights to co's suite of products with U.S.
P

Europe's STOXX 600 corporate earnings week ahead

DIARY-Europe's STOXX 600 corporate earnings week ahead Sept 13 (Reuters) - Diary of Europe's STOXX 600 (.STOXX) corporate earnings for the week ahead EUROPE'S STOXX 600 EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 16-Sep-2024 13:30 BARN.S Barry Callebaut AG Barry Callebaut AG EUDR Investor Webinar 16-Sep-2024 NTS PHNX.L Phoenix Group Holdings PLC Half Year 2024 Phoenix Group Holdings PLC Earnings Release 17-Sep-2024 BMO KGF.L Kingfisher PLC Half Year 2025 Kingfisher PLC Earni
A
K
N
P
P

Baby bottle maker says microplastics inescapable, health risks unproven, in bid to toss lawsuit

UPDATE 1-Baby bottle maker says microplastics inescapable, health risks unproven, in bid to toss lawsuit Adds comment from attorneys for the consumers in paragraph 4 and 5 and comment from Philips in paragraph 6, fixes style in case info at end By Diana Novak Jones Sept 9 (Reuters) - Handi-Craft Co on Friday pushed back against claims that the company failed to warn parents that their plastic baby bottles leach microplastics when heated, arguing in part that microplastics are ubiquitous and thei
P

Baby bottle maker says microplastics inescapable, health risks unproven, in bid to toss lawsuit

Baby bottle maker says microplastics inescapable, health risks unproven, in bid to toss lawsuit By Diana Novak Jones Sept 9 (Reuters) - Handi-Craft Co on Friday pushed back against claims that the company failed to warn parents that their plastic baby bottles leach microplastics when heated, arguing in part that microplastics are ubiquitous and their health effects are unproven.
P

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.